LB PharmaceuticalsLBRX -2.40%12 Net-Net Working Capital is $12.24 as of Mar. 2026. GuruFocus rates LBRX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 860 Biotechnology companies, LB Pharmaceuticals ranks better than 72.67% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
LB Pharmaceuticals's Net-Net Working Capital for the quarter that ended in Mar. 2026 was $12.24.
The industry rank for LB Pharmaceuticals's Net-Net Working Capital or its related term are showing as below:
LBRX's Price-to-Net-Net-Working-Capital is ranked better than 72.67% of 860
companies
in the Biotechnology industry
Industry Median: 5.545
vs LBRX: 2.69
LB Pharmaceuticals (NAS:LBRX) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
LB Pharmaceuticals Net-Net Working Capital Related Terms
LB Pharmaceuticals Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for LB Pharmaceuticals's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LBRX vs MRVI, SLDB, JANX: Net-Net Working Capital Comparison
For the Biotechnology subindustry, LB Pharmaceuticals's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LB Pharmaceuticals Price-to-Net-Net-Working-Capital vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LB Pharmaceuticals's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where LB Pharmaceuticals's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $12.24 mean?
LB Pharmaceuticals (LBRX) has a Net-Net Working Capital of $12.24 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on LB Pharmaceuticals According to the industry distribution chart, LB Pharmaceuticals ranks #235 out of 860 companies in the Biotechnology industry, placing it in the top 27.3%.
Is LB Pharmaceuticals' Net-Net Working Capital too high?
LB Pharmaceuticals' current Net-Net Working Capital is $12.24. The Biotechnology industry median Net-Net Working Capital is 5.55. LB Pharmaceuticals' value of $12.24 is 120.7% above this industry median. Based on the distribution chart, LB Pharmaceuticals ranks #235 out of 860 companies in the Biotechnology industry, which is above the industry midpoint. Overall, LB Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LB Pharmaceuticals' Net-Net Working Capital compare to MRVI and SLDB?
According to the Biotechnology industry distribution chart, LB Pharmaceuticals ranks #235 out of 860 companies for Net-Net Working Capital. This puts LB Pharmaceuticals in the upper half of its industry. The industry median Net-Net Working Capital is 5.55. LB Pharmaceuticals' value of $12.24 is 120.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Biotechnology company?
The median Net-Net Working Capital among Biotechnology companies is 5.55, based on 860 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LB Pharmaceuticals's current Net-Net Working Capital of $12.24 is 120.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on LB Pharmaceuticals For the Biotechnology industry, the median Net-Net Working Capital is 5.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LB Pharmaceuticals's current Net-Net Working Capital is $12.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LB Pharmaceuticals stock overvalued right now?
LB Pharmaceuticals (LBRX) has a current Net-Net Working Capital of $12.24. The current Net-Net Working Capital is $12.24 and 120.7% above the Biotechnology industry median of 5.55. LB Pharmaceuticals' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For LB Pharmaceuticals (LBRX), the current Net-Net Working Capital is $12.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
12GF Score
Get the complete analysis for LBRX
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LBRX has been successfully added to your 
